All News Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Market Closed - Nasdaq Stockholm Other stock markets 11:29:54 2024-05-10 am EDT			5-day change	1st Jan Change
0.2295 ^SEK	+20.54%		+13.61%	-97.70%

May. 10	Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	MT
May. 02	Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	May. 10	MT
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US	May. 10	AQ
Announcement from Xbrane Biopharma's annual general meeting	May. 02	AQ
Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director	May. 02	CI
Transcript : Xbrane Biopharma AB - Special Call	Apr. 22
Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate	Apr. 21	AQ
Notice of annual general meeting in Xbrane Biopharma AB	Apr. 02	AQ
Change of number of shares and votes in Xbrane	Apr. 01	AQ
XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023	Mar. 27	AQ
Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue	Mar. 19	AQ
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index	Mar. 17	CI
Xbrane announces the outcome of the rights issue	Mar. 14	AQ
Xbrane publish supplement to prospectus	Mar. 08	AQ
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	Mar. 04	AQ
Xbrane Biopharma Q4 2023 - Navigating muddy waters	Mar. 01	AQ
Trading in unit rights and BTUs in Xbrane's rights issue will commence on 29 February 2024	Feb. 27	AQ
Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million	Feb. 27	AQ
Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024	Feb. 26
Xbrane Biopharma releases Year-end Report 2023	Feb. 26	AQ
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

All News

Filters